Your browser doesn't support javascript.
COVID-19 Lockdown Periods in 2020: Good Maintenance of Metabolic Control in Adults with Type 1 and Type 2 Diabetes.
Hartmann, B; Tittel, S R; Femerling, M; Pfeifer, M; Meyhöfer, S; Lange, K; Milek, S; Stemler, L; Best, F; Holl, R W.
  • Hartmann B; Heilig-Geist Hospital, Department of Gastroenterology and Diabetology, Bensheim, Germany.
  • Tittel SR; Institute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany.
  • Femerling M; German Centre for Diabetes Research (DZD), Munich-Neuherberg, Germany.
  • Pfeifer M; Praxis Prinzenstraße, Eckernförde, Germany.
  • Meyhöfer S; Klinik Tettnang GmbH, Tettnang, Germany.
  • Lange K; German Centre for Diabetes Research (DZD), Munich-Neuherberg, Germany.
  • Milek S; University of Lübeck, Institute for Endocrinology and Diabetes, Lübeck, Germany.
  • Stemler L; Department of Internal Medicine 1, Endocrinology & Diabetes, University of Lübeck, Lübeck, Germany.
  • Best F; Hanover Medical School, Department of Medical Psychology, Hanover, Germany.
  • Holl RW; Diabetes-Schwerpunkt und Schulungspraxis, Hohenmölsen, Germany.
Exp Clin Endocrinol Diabetes ; 130(9): 621-626, 2022 Sep.
Article in English | MEDLINE | ID: covidwho-1705904
ABSTRACT
During the COVID-19 pandemic, there were increased concerns about glycemic control in patients with diabetes. Therefore, we aimed to assess changes in diabetes management during the COVID-19 lockdown for patients with type 1 or type 2 diabetes mellitus (T1DM, T2DM) in Germany. We included data from 24,623 patients (age>18 years) with T1DM (N=6,975) or T2DM (N=17,648) with documented data in 2019 and 2020 from the multicenter Diabetes-Prospective Follow-up registry (DPV). We conducted a groupwise comparison of identical patients in 2019 and 2020 for different time periods of pandemia. Pairwise differences of continuous parameters of treatment modalities and metabolic outcome between 2019 and 2020 were adjusted for seasonality, age, and diabetes duration. We presented these outcomes as adjusted medians with 95% confidence intervals. Rates were compared using negative-binomial models, dichotomous outcomes were compared using logistic models. Models were additionally adjusted for age and diabetes duration. These outcomes were presented as least-square means with 95% confidence intervals, p-values of<.05 were considered significant.In participants with T1DM, CGI (combined glucose indicator) increased only by 0.11-0.12% in all time periods of 2020 compared to 2019 (all p<0.001) while BMI decreased slightly by -(0.09-0.10) kg/m² (p<0.0001). In participants with T2DM, HbA1c increased by 0.12%, while BMI decreased slightly by -(0.05-0.06) kg/m² (p<0.0001).During the COVID-19 lockdown period, patients with T1DM and T2DM experienced only clinically insignificant changes in glucose control or body weight. Despite lockdown restrictions, patients were able to maintain metabolic control.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetes Mellitus, Type 1 / Diabetes Mellitus, Type 2 / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Limits: Adolescent / Adult / Humans Language: English Journal: Exp Clin Endocrinol Diabetes Journal subject: Endocrinology Year: 2022 Document Type: Article Affiliation country: A-1743-2537

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetes Mellitus, Type 1 / Diabetes Mellitus, Type 2 / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Limits: Adolescent / Adult / Humans Language: English Journal: Exp Clin Endocrinol Diabetes Journal subject: Endocrinology Year: 2022 Document Type: Article Affiliation country: A-1743-2537